Aucubin
Based on 11 publication(s) in Google Scholar
Aucubin is an iridoid glycoside component that acn be found in E. ulmoides. Aucubin can cross the blood-brain barrier (BBB) and has anti-anxiety, antidepressive and anti-neuroinflammatory effects. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 479-98-1
- Formel: C15H22O9
- Molecular Weight:346.33
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Aucubin
More- Nat Cell Biol. 2026 Jun;28(6):1204-1218. [Abstract]
- Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]
- Biochem Pharmacol. 2023 Mar:209:115440. [Abstract]
- Pharmaceuticals (Basel). 2023 Nov 1;16(11):1545. [Abstract]
- Int Immunopharmacol. 2024 Mar 10:129:111648. [Abstract]
- Int Immunopharmacol. 2024 Jan 5:126:111312. [Abstract]
- Bioorg Chem. 2026 Jan:168:109332. [Abstract]
- Viruses. 2025 Apr 27;17(5):628. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Medicine (Baltimore). 2024 Oct 25;103(43):e40211. [Abstract]
- Research Square Preprint. 2021 Feb.
Customer Validation & Images
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
>10 μM
Compound: 24
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 26859776] |
| A549 | IC50 |
>10 μM
Compound: 24
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 26859776] |
| Bel-7402 | IC50 |
>10 μM
Compound: 24
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 26859776] |
| BGC-823 | IC50 |
>10 μM
Compound: 24
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 26859776] |
| HT-29 | IC50 |
>10 μM
Compound: 24
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 26859776] |
Aucubin (0.001-1 μg/mL; pretreated for 30 min) dose-dependently inhibits IgE-induced TNF-α and IL-6 production and expression in RBL-2H3 cells, with IC50s of 0.101 and 0.19 μg/mL, respectively[2].
Aucubin (0.01 μg/mL; pretreated for 30 min) inhibits IgE-induced nuclear translocation of p65 subunit of NF-κB and degradation of IκBα in RBL-2H3 cells[2].
Aucubin (0.001-1 mM; 12 h) increases PC12 cellular viability and markedly inhbits H2O2-induced apoptotic cell death[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aucubin (40-200 mg/kg; a single i.p.) exhibits significant protective activity against α-amanitin intoxication in mice[5].
Aucubin (5 mg/kg/day; i.p. for 21 d) decreases the breathing frequency, increases the lung dynamic compliance, alleviates lung parenchymal fibrotic changes, and reduces the intrapulmonary collagen disposition and inflammatory injury of BLM-stimulated mice[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (200-230 g) induced diabetes by a injection of streptozotocin[1]
-
Dosage:5 mg/kg
-
Administration:I.p. twice daily for the first 5 days, followed by single injections daily for the last 10 days
-
Result:Increased the body weight of streptozotocin-diabetic rats.
Lowered the blood glucose level.
Decreased the level of lipid peroxidation and increased the activities of antioxidant enzymes.
Increased in insulin immunoreactivity and the number of immunoreactive β cells compared with untreated diabetic rats.
Chemical Information
-
CAS. Nr. 479-98-1
-
Appearance Solid
-
Molecular Weight 346.33
-
Formel C15H22O9
-
Color White to light yellow
-
SMILES
O[C@H]([C@@H](O)[C@@H]1O)[C@](O[C@@H]1CO)([H])O[C@H](OC=C2)[C@@]3([H])[C@]2([H])[C@H](O)C=C3CO
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
2026 Jun;28(6):1204-1218. PMID: 42174134 -
Stem Cell Res Ther
Aucubin promotes bone-fracture healing via the dual effects of anti-oxidative damage and enhancing osteoblastogenesis of hBM-MSCs. [Abstract]2022 Aug 19;13(1):424. PMID: 35986345
Aucubin purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]
Aubucin (AU, 0.01-1 μmol/L). Immunofluorescence staining for COL1A1 and RUNX2 proteins after 3 days of osteogenesis. Scale bars, 50 μm. Western blotting analysis indicated that the protein expression of osteogenesis-related genes (COL1A1, RUNX2 and SP7) was significantly increased at concentrations of 0.1 μM and 1 μM on day 3 of osteogenesis compared to control group.
Aucubin purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]
Different concentrations of Aubucin (AU, 0–1 μM) promoted hBM-MSCs mineralization and ALP activity. ALP staining and activity was detected on day 3 of osteogenesis. ARS staining and quantitation was detected on day 14 of osteogenesis. Scale bars, 500 μm.
-
Biochem Pharmacol
Aucubin protects mouse cochlear hair cells from cisplatin-induced ototoxicity via activation of the PI3K/AKT/STAT3 pathway. [Abstract]2023 Mar:209:115440. PMID: 36720354
Aucubin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Mar:209:115440. [Abstract]
The cultured mice cochlear explants were divided into control (no treatment), cisplatin only (20 μM cisplatin for 24 h), Aucubin only (Au, 150 μM Aucubin for 24 h), and cisplatin plus Aucubin (150 μM Aucubin pre-treatment for 4 h, followed by combined cisplatin and Aucubin treatment for 24 h) groups. Representative images showing that the apical, middle, and basal turns of the cochlear explants treated with cisplatin plus Aucubin (Cis + Au) had significantly more HCs compared to the cisplatin group (Cis).
Aucubin purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Mar:209:115440. [Abstract]
6 mice were administered 20 μM cisplatin in the right ear and 20 μM cisplatin plus 150 μM Aucubin (Au,single dose) in the left ear, while another 6 mice were administered 150 μM Aucubin in the right ear and equivalent normal saline in the left ear. Transtympanic injection of Aucubin injection substantially alleviated the ABR threshold shift caused by cisplatin at 8, 16, and 22.6 kHz. n = 6.
-
Pharmaceuticals (Basel)
The Analgesia Effect of Aucubin on CFA-Induced Inflammatory Pain by Inhibiting Glial Cells Activation-Mediated Inflammatory Response via Activating Mitophagy. [Abstract]2023 Nov 1;16(11):1545. PMID: 38004411
Aucubin purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2023 Nov 1;16(11):1545. [Abstract]
Aucubin (10 mg/kg; i.p.; once daily for 3 days) attenuated CFA-induced mechanical allodynia and thermal hyperalgesia in mice.
-
Int Immunopharmacol
2024 Mar 10:129:111648. PMID: 38335656
Aucubin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Mar 10:129:111648. [Abstract]
Microglia was pretreated with various concentrations of AU (Aucubin; 50-100 μM) for 2 h followed by LPS treatment (100 ng/ml). The mRNA levels of TNF-α, IL‐1β, iNOS, and IL‐6 were measured using real‐time PCR after LPS treatment for 24 h with or without AU.
Aucubin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Mar 10:129:111648. [Abstract]
Primary microglia were treated with/without AU (Aucubin) in a dose-dependent manner (0,1,10,100,500,1000 and 10000 μM) for 24 h, then CCK-8 assay was added to detect cell viability, respectively. n = 4 per group. AU at lower concentrations (0 to 500 μM) didn't affect the microglial viability, whereas higher concentrations (1000 to 10000 μM) of AU significantly decreased microglial viability.
-
Int Immunopharmacol
Attenuated memory impairment and neuroinflammation in Alzheimer's disease by aucubin via the inhibition of ERK-FOS axis. [Abstract]2024 Jan 5:126:111312. PMID: 38043266 -
Bioorg Chem
Aucubin attenuates neonatal hypoxic-ischemic brain injury by suppressing NLRP3 inflammasome-mediated microglial pyroptosis. [Abstract]2026 Jan:168:109332. PMID: 41365065 -
Viruses
Anthraquinone-2-Carboxylic Acid Is a Potential Antiviral Candidate Against Influenza Viruses In Vitro and In Vivo. [Abstract]2025 Apr 27;17(5):628. PMID: 40431640 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Medicine (Baltimore)
Integrating network pharmacology, molecular docking, and experimental validation to reveal the mechanism of Radix Rehmanniae in psoriasis. [Abstract]2024 Oct 25;103(43):e40211. PMID: 39470475 -
Lösungsmittel & Löslichkeit
H2O : ≥ 100 mg/mL (288.74 mM)
DMSO : 100 mg/mL (288.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Jin l, et, al. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol. 2008 Mar 17;582(1-3):162-7. [Content Brief]
[2]. Jeong HJ, et, al. Inhibition of TNF-alpha and IL-6 production by Aucubin through blockade of NF-kappaB activation RBL-2H3 mast cells. Cytokine. 2002 Jun 7;18(5):252-9. [Content Brief]
[3]. Zeng X, et, al. A review of the pharmacology and toxicology of aucubin. Fitoterapia. 2020 Jan;140:104443. [Content Brief]
[4]. Xue HY, et, al. Protective effects of aucubin on H₂O₂-induced apoptosis in PC12 cells. Phytother Res. 2012 Mar;26(3):369-74. [Content Brief]
[5]. Chang LM, et, al. Aucubin: potential antidote for alpha-amanitin poisoning. J Toxicol Clin Toxicol. 1984 Jul;22(1):77-85. [Content Brief]
[6]. Zhou Y, et, al. Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Model. Inflammation. 2017 Dec;40(6):2062-2073. [Content Brief]
[7]. Liu P, et al. Aucubin improves chronic unpredictable mild stress-induced depressive behavior in mice via the GR/NF-κB/NLRP3 axis. Int Immunopharmacol. 2023 Oct;123:110677. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.8874 mL | 14.4371 mL | 28.8742 mL | 72.1855 mL |
| 5 mM | 0.5775 mL | 2.8874 mL | 5.7748 mL | 14.4371 mL | |
| 10 mM | 0.2887 mL | 1.4437 mL | 2.8874 mL | 7.2185 mL | |
| 15 mM | 0.1925 mL | 0.9625 mL | 1.9249 mL | 4.8124 mL | |
| 20 mM | 0.1444 mL | 0.7219 mL | 1.4437 mL | 3.6093 mL | |
| 25 mM | 0.1155 mL | 0.5775 mL | 1.1550 mL | 2.8874 mL | |
| 30 mM | 0.0962 mL | 0.4812 mL | 0.9625 mL | 2.4062 mL | |
| 40 mM | 0.0722 mL | 0.3609 mL | 0.7219 mL | 1.8046 mL | |
| 50 mM | 0.0577 mL | 0.2887 mL | 0.5775 mL | 1.4437 mL | |
| 60 mM | 0.0481 mL | 0.2406 mL | 0.4812 mL | 1.2031 mL | |
| 80 mM | 0.0361 mL | 0.1805 mL | 0.3609 mL | 0.9023 mL | |
| 100 mM | 0.0289 mL | 0.1444 mL | 0.2887 mL | 0.7219 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Aucubin Related Classifications
HY-N0664 Related Classifications
Powered by Bioz